Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis Chooses BlueArc for Storage Architecture

NEW YORK, March 11 - The chemical genomics company NeoGenesis has chosen BlueArc to provide a storage architecture for its drug discovery data, the companies said today.


NeoGenesis, of Cambridge, Mass., has an automated ligand identification system for screening protein targets associated with disease, and a NeoMorph compound library of 10 million molecules. The company said it generates between five and 20 gigabytes of data per day, per screening line, and can generate more than 2 terabytes per month, with the requirement that the data remain online for about three months. 


Blue Arc's Si7500 SiliconServer architecture has been installed at NeoGenesis to store data from its work.


"BlueArc's hardware-based solution eliminates the dependency on software, which we saw as a crippling factor in other NAS solutions," Tomas Revesz, director of Information Systems for NeoGenesis, said in a statement.


This deal comes as BlueArc, of San Jose, Calif., makes a public foray into the life sciences with the establishment of a life sciences IT practice.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.